GH1 and BAP1-related tumor predisposition syndrome: Currently, only limited data are available on the efficiency of growth hormone treatment in the different molecular subgroups, but it is has to be taken into account that some of the differential diagnosis of SRS are tumour predisposition syndromes [3].